Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.48 |
| ▸ | ITGAV | P06756 | 14/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.45 |
| ▸ | MC4R | P32245 | 2/20 | 0.44 |
| ▸ | MC5R | P33032 | 2/20 | 0.44 |
| ▸ | MC3R | P41968 | 2/20 | 0.44 |
| ▸ | MC1R | Q01726 | 2/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918138 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL2534766 | 0.88 | ITGB3 (0.48) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL17029693 | 0.82 | ITGB3 (0.45) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL17023189 | 0.82 | ITGB3 (0.47) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL17029683 | 0.81 | ITGB3 (0.57) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL2536491 | 0.81 | ITGB3 (0.50) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL15107694 | 0.80 | ITGB3 (0.48) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL19605483 | 0.80 | ITGB3 (0.57) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL13465281 | 0.80 | ITGB3 (0.49) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL18080800 | 0.80 | ITGB3 (0.49) | ITGB3ITGAVITGA5ITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182974-B1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8486372-B2 | Cyclic azapeptides as integrin markers and methods of using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009018175-A2 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | ITGAV, ITGB3, ITGA2B | ITGB3 2/4885ITGAV 1/4885ITGA5 17/4885 |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | ITGAV, ITGB3, ITGA2B | ITGB3 2/4885ITGAV 1/4885ITGA5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.